News from regeneron pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 25, 2014, 01:00 ET

Regeneron and Sanofi to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at ESC Congress 2014

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that details from four pivotal trials...

Aug 19, 2014, 09:30 ET

Regeneron Announces Upcoming 2014 Investor Conference Presentations

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences: - Sanofi...

Aug 11, 2014, 02:30 ET

EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA® (aflibercept) Injection has been approved by the European...

Aug 05, 2014, 06:30 ET

Regeneron Reports Second Quarter 2014 Financial and Operating Results

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2014 and provided an update on...

Jul 30, 2014, 16:01 ET

Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that the Companies intend to use a...

Jul 30, 2014, 08:00 ET

Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that nine new Phase 3 ODYSSEY trials...

Jul 30, 2014, 08:00 ET
http://www.multivu.com/players/English/7268451-sanofi-and-regeneron-results-from-nine-phase-3-trials-of-alirocumab/gallery/image/840e9af2-54e1-416f-9460-100f608efecd.HR.jpg

Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia

Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that nine new Phase 3 ODYSSEY trials of...

Jul 29, 2014, 18:32 ET

EYLEA® (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME)

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA®...

Jul 18, 2014, 16:01 ET

Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2014

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2014 financial and operating results...

Jul 18, 2014, 06:00 ET

Two-Year Results From Phase 3 VIVID-DME Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the...

Jul 09, 2014, 17:00 ET

Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced positive results from a Phase 2b...

Jun 27, 2014, 07:17 ET

EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA® (aflibercept) Injection has been recommended for approval by...

Jun 12, 2014, 01:00 ET

Sanofi and Regeneron Announce New, Detailed Data from Positive Sarilumab Phase 3 Rheumatoid Arthritis Trial at EULAR

 Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today presented positive results from a phase 3...

Jun 11, 2014, 02:30 ET

EYLEA® (aflibercept) Injection Submitted for EU Marketing Authorization for the Treatment of Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that Bayer HealthCare has submitted an application to the...

Jun 02, 2014, 17:03 ET

Regeneron Announces Winners of the 2014 Regeneron Prize for Creative Innovation

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the second annual winners of the Regeneron Prize for Creative Innovation, an...

May 30, 2014, 16:05 ET

Regeneron Announces Update to Upcoming 2014 Investor Conference Presentations

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its management presentation at the following investor conferences: - Jefferies...

May 08, 2014, 06:30 ET

Regeneron Reports First Quarter 2014 Financial and Operating Results

 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced financial results for the first quarter of 2014 and provided an update on...

May 05, 2014, 08:27 ET

Regeneron and Avalanche Biotechnologies Announce Collaboration to Develop Next-Generation Gene Therapy Products in Ophthalmology

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Avalanche Biotechnologies, Inc., today announced the formation of a broad collaboration to...

May 02, 2014, 09:30 ET

Regeneron Announces Upcoming 2014 Investor Conference Presentations

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences: - Citi Biotech...

Apr 11, 2014, 09:30 ET

Regeneron to Report First Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on May 8, 2014

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2014 financial and operating results...